- Home
- GLPG vs RHI Comparison
GLPG vs RHI Comparison
Compare GLPG & RHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLPG | RHI |
|---|---|---|
| Founded | 1999 | 1948 |
| Country | Belgium | United States |
| Employees | 704 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.6B |
| IPO Year | N/A | 1994 |
Fundamental Metrics
Financial Performance| Metric | GLPG | RHI |
|---|---|---|
| Price | $32.47 | $23.16 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 6 |
| Target Price | ★ $36.50 | $30.33 |
| AVG Volume (30 Days) | 90.9K | ★ 3.3M |
| Earning Date | 01-01-0001 | 04-30-2026 |
| Dividend Yield | N/A | ★ 10.17% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.33 |
| Revenue | N/A | ★ $5,378,506,000.00 |
| Revenue This Year | N/A | $1.57 |
| Revenue Next Year | N/A | $6.00 |
| P/E Ratio | ★ N/A | $17.50 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.59 | $22.32 |
| 52 Week High | $37.78 | $55.24 |
Technical Indicators
Market Signals| Indicator | GLPG | RHI |
|---|---|---|
| Relative Strength Index (RSI) | 39.61 | 36.70 |
| Support Level | $32.07 | $22.32 |
| Resistance Level | $33.56 | $28.35 |
| Average True Range (ATR) | 0.79 | 1.16 |
| MACD | -0.15 | -0.03 |
| Stochastic Oscillator | 1.66 | 15.66 |
Price Performance
Historical ComparisonAbout GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About RHI Robert Half Inc.
Robert Half Inc was founded in 1948, Robert Half provides temporary, permanent, and outcome-based staffing for both in-person and remote positions in the finance and accounting, technology, legal, marketing, and administrative fields. Its subsidiary consulting arm, Protiviti, specializes in technology, risk, auditing, and compliance matters. The firm generates its sales inside the U.S. and is one of the specialized firms in the fragmented U.S. staffing industry.